脂必泰联合辛伐他汀对肾病综合征患者高脂血症的疗效  

Efficacy of zhibitai combined with simvastatin on hyperlipidemia in patients with nephrotic syndrome

作　　者：高丹[1] 明静[1] 刘晶晶[1] 

机构地区：[1]湖北省襄阳市中心医院肾内科,湖北襄阳441021

出　　处：《实用药物与临床》2013年第3期223-224,共2页Practical Pharmacy and Clinical Remedies

摘　　要：目的观察脂必泰联合辛伐他汀对肾病综合征患者高脂血症的疗效。方法 30例肾病综合征患者随机分为辛伐他汀组(对照组,14例)和辛伐他汀联合脂必泰组(联合组,16例),治疗前后分别检测两组患者血浆蛋白、血脂、24 h尿蛋白。结果两组治疗8周后血脂均明显下降(P<0.05),血浆白蛋白明显升高(P<0.05),尿白蛋白显著下降(P<0.05)。与对照组相比,联合组血脂及尿蛋白下降更多(P<0.05);血浆蛋白升高程度高于对照组(P<0.05)。结论脂必泰联合辛伐他汀能明显降低肾病综合征患者血脂水平和尿蛋白,升高血浆蛋白,疗效优于单独应用辛伐他汀。Objective To observe and compare the efficacy of zhibitai combined with simvastatin on hyperlipidemia in patients with nephritic syndrome（NS）. Methods 30 patients with NS were randomly divided into simvastatin group（n=14,control group）and zhibitai combined with simvastatin group（n=16,combined group）.The liver function,serum lipid and 24 hours uninary protein were detected before and 8 weeks after therapy. Results The blood lipid and urinary albumin increased,and the serum albumin decreased,there was significant difference between the two groups 8 weeks after therapy than before（P〈0.05）.Compared with control group,TC,TG,and LDL-C in combined group significantly decreased（P〈0.05）.TP and ALB in combined group significantly increased than those in control group（P〈0.05）. Conclusion For nephritic syndrome,zhibitai combined simvatatin can markedly decrease levels of serum lipid and urinary protein,increase levels of TP,ALB and has better efficacy than simvatatin alone.

关 键 词：肾病综合征 高脂血症 调节血脂药物 

分 类 号：R692.3[医药卫生—泌尿科学] R589.2[医药卫生—外科学]